Asked by: James MacCleary (Liberal Democrat - Lewes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential duplication of (a) regulatory and (b) inspection activity in adult social care between the (i) Care Quality Commission and (ii) local authority adult social care services.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
There is no direct duplication between how the Care Quality Commission (CQC) assesses individual registered providers and how local authorities oversee providers within their areas. Both bodies are involved in evaluating quality and safety, but they do so under different legislative frameworks and for distinct purposes.
The CQC’s remit is to assess registered providers against the Health and Social Care Act 2008 (Regulated Activities) Regulations 2014. The CQC monitors, inspects, and regulates services to make sure they meet fundamental standards of quality and safety. Local authorities are responsible for ensuring registered adult social care providers deliver care that meets people’s needs and the duties as set out in the Care Act 2014. Their oversight thus tends to focus on quality, safeguarding, and contract compliance. The CQC works with local authorities to share information and intelligence and are working on ways to strengthen these links.
Similarly, there is no direct duplication between how the CQC assesses individual registered providers and how the CQC assesses local authorities. CQC provider regulation assesses against the Health and Social Care Act 2008, whereas local authority assessments assess against the Care Act 2014. Both pieces of legislation require different methodology, however they can be used to inform each other.
The commission into adult social care is independent of the Government, and Baroness Casey has the autonomy to define her own engagement plans, including with ministers, based on what she believes is most appropriate for the commission’s work.
Asked by: James MacCleary (Liberal Democrat - Lewes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has had discussions with the Casey Commission on the potential duplication of (a)regulatory and (b) inspection activity in adult social care.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
There is no direct duplication between how the Care Quality Commission (CQC) assesses individual registered providers and how local authorities oversee providers within their areas. Both bodies are involved in evaluating quality and safety, but they do so under different legislative frameworks and for distinct purposes.
The CQC’s remit is to assess registered providers against the Health and Social Care Act 2008 (Regulated Activities) Regulations 2014. The CQC monitors, inspects, and regulates services to make sure they meet fundamental standards of quality and safety. Local authorities are responsible for ensuring registered adult social care providers deliver care that meets people’s needs and the duties as set out in the Care Act 2014. Their oversight thus tends to focus on quality, safeguarding, and contract compliance. The CQC works with local authorities to share information and intelligence and are working on ways to strengthen these links.
Similarly, there is no direct duplication between how the CQC assesses individual registered providers and how the CQC assesses local authorities. CQC provider regulation assesses against the Health and Social Care Act 2008, whereas local authority assessments assess against the Care Act 2014. Both pieces of legislation require different methodology, however they can be used to inform each other.
The commission into adult social care is independent of the Government, and Baroness Casey has the autonomy to define her own engagement plans, including with ministers, based on what she believes is most appropriate for the commission’s work.
Asked by: James MacCleary (Liberal Democrat - Lewes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps is his Department taking to support people (a) injured or (b) bereaved by AstraZeneca COVID-19 vaccinations, including those with vaccine-induced thrombocytopenia and thrombosis.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
In the very rare event where someone may have suffered a severe adverse reaction to a vaccine, care and treatment will be best managed by local National Health Service specialist services, augmented as appropriate by national specialist advice. Individuals will be treated and managed through existing healthcare services, with treatment dependent on the individual’s clinical needs.
Individuals can also apply to the Vaccine Damage Payment Scheme (VDPS) which provides a one-off, tax-free payment of £120,000 to claimants who have been found, on the balance of probabilities, to have been severely disabled as a result of vaccinations against certain diseases listed in the Vaccine Damage Payments Act 1979.
Outside of the VDPS, other Government support remains available for those with a disability or long-term health condition, including Statutory Sick Pay, Universal Credit, Employment and Support Allowance, Attendance Allowance, and Personal Independence Payments. Further information is available at the following link:
https://www.gov.uk/browse/benefits/disability
Asked by: James MacCleary (Liberal Democrat - Lewes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what criteria his Department uses to determine which conditions should receive a modern service framework; and whether respiratory health meets these criteria.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Everyone in the National Health Service is responsible for delivering high-quality care. As announced in the 10-Year Health Plan, as well as an overall quality strategy, the National Quality Board will oversee the development of a new series of service frameworks to accelerate progress in conditions where there is potential for rapid and significant improvements in the quality of care and productivity.
Early priorities will include cardiovascular disease, severe mental illness, and the first ever service framework for frailty and dementia. The Government will consider other long-term conditions with significant health and economic impacts for future waves of modern service frameworks.
Asked by: James MacCleary (Liberal Democrat - Lewes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department plans to take to help (a) increase capacity and (b) tackle inequalities in accessing a respiratory diagnosis.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Government is committed to increasing the capacity of respiratory services and is improving access to these services through new community diagnostic centres (CDCs).
All standard and large CDCs are required to offer diagnostic respiratory tests such as spirometry and full lung function tests as part of their core testing offer.
The 2025/26 capital guidance confirmed that £1.65 billion of capital funding is being allocated to support National Health Service performance across secondary and emergency care across 2025/26 more broadly. This includes funding to enable the completion of 2024/25 CDC schemes, as well as to expand existing and build new CDCs.
Asked by: James MacCleary (Liberal Democrat - Lewes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what steps his Department plans to take to help reduce the impact of chronic respiratory conditions on the NHS in winter 2025-26.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
NHS England, working with the Department, the UK Health Security Agency, and other partners, is taking action to reduce the impact of respiratory conditions on the National Health Service this winter. This includes robust, consistent infection prevention and control measures, and a campaign to encourage eligible people to get their winter vaccinations. Further information on the actions being taken to reduce the demand on acute services during winter is available at the following link:
https://www.england.nhs.uk/long-read/urgent-and-emergency-care-plan-2025-26/
Asked by: James MacCleary (Liberal Democrat - Lewes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of classifying stage 4 breast cancer as very severe in relation to access to life-saving drugs.
Answered by Zubir Ahmed - Parliamentary Under-Secretary (Department of Health and Social Care)
The Department understands the impact that cancer has on those living with it and their families, and the urgent need for new treatment options.
The National Institute for Health and Care Excellence (NICE) is an independent body and is responsible for developing the methods and processes it uses to evaluate whether new medicines should be recommended for routine National Health Service funding.
Whilst no such assessment has been made, in developing recommendations on whether medicines represent a clinically and cost-effective use of NHS resources, NICE is able to apply a weighting that recognises the additional value that society places on treatments for severe conditions. The weighting that is applied is calculated for each appraisal based on information on the expected shortfall in life expectancy and quality of life of people with the condition, considering existing treatment options. NICE has concluded for several appraisals of medicines for late-stage breast cancer that a weighting should be applied based on the severity of the condition and has recommended all but one of the new medicines for the treatment of breast cancer, including advanced breast cancer, that it has evaluated since 2018. These treatments are now available for the treatment of NHS patients.
NICE’s methods that are used for determining whether an appraisal qualifies for a weighting under the severity modifier have been developed through extensive engagement with stakeholders and through public consultation.
Asked by: James MacCleary (Liberal Democrat - Lewes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of the availability of (a) child psychologists and (b) other qualified specialists to assess severely disabled children for (i) ADHD and (ii) other neurodevelopmental conditions where (A) a lack of assessment prevents access to appropriate medication and support and (B) in other circumstances.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Government has recognised that, nationally, demand for assessments for autism and attention deficit hyperactivity disorder (ADHD) has grown significantly in recent years and that people are experiencing severe delays for accessing such assessments. The government’s 10 Year Health Plan will make the National Health Service fit for the future, recognising the need for early intervention and support, without the need for diagnosis.
It is the responsibility of integrated care boards (ICBs) to make appropriate provision to meet the health and care needs of their local population, including access to ADHD and autism assessments and support, in line with relevant National Institute for Health and Care Excellence guidelines.
NHS England has established an ADHD taskforce which is bringing together those with lived experience with experts from the NHS, education, charity and justice sectors to get a better understanding of the challenges affecting those with ADHD, including in accessing services and support. An interim report was published on 20 June, with the final report expected to be published later in the year and we will carefully consider its recommendations.
The Government is supporting inclusive environments for children with special educational needs and disabilities (SEND) through the ‘Partnerships for Inclusion of Neurodiversity in Schools’ programme and earlier intervention through the ‘Early Language Support for Every Child’ programme. In addition, through local commissioning, the Government will ensure that Neighbourhood Health Services work in partnership with family hubs, schools, nurseries and colleges to offer timely and joined-up support to children, young people and their families.
Asked by: James MacCleary (Liberal Democrat - Lewes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what assessment he has made of the adequacy of NHS surgery waiting time information published on the NHS My Care Portal in the context of reports that these timeframes differ from those provided by NHS hospital trusts.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
Patients in England can choose the hospital for their first outpatient appointments via the NHS e-Referral Service and the NHS App, allowing them to view and choose from available appointments across different hospitals within the same region.
The National Health Service is a large, decentralized system, and individual NHS hospital trusts are responsible for managing their own patient portals, resulting in different systems and features. Each trust may set its own policies and internal delays before results are displayed in the portal, rather than linking them directly to the patient. A delay in displaying results is a common practice for sensitive test results linked to conditions such as cancer, to give doctors an opportunity to review them with the patient first.
The NHS ensures adequate data for My Planned Care by employing a multi-faceted approach, including centralised data collection and curation, implementing shared records for better data integration across systems, establishing robust data quality checks and reporting, adhering to strict information governance and security standards, and actively working to link diverse data sources. These processes support the provision of timely and accurate information on the My Planned Care website to help patients and healthcare professionals.
The NHS continues to invest heavily in the NHS App and in the past two years we have been implementing digital integration between acute hospitals and the NHS App, meaning that patients can now view their clinical pathway and appointments via the NHS App. We continue to work with hospital trusts to maximise the opportunities available to update patients via the NHS App, which is a key part of the 10-year plan to reform the NHS.
The NHS App has now been adopted by 88% of acute trusts, up nearly 20% since July 2024, which enables patients to view and manage their hospital appointments.
Analysis shows that hospitals that make the changes to plug their systems and processes into the NHS App key app features have improved elective care waiting times.
Asked by: James MacCleary (Liberal Democrat - Lewes)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, if he will make an assessment of the accuracy of the classification of stage 4 breast cancer as moderate in severity.
Answered by Ashley Dalton - Parliamentary Under-Secretary (Department of Health and Social Care)
Neither the Department for Health and Social Care nor the National Institute for Health and Care Excellence (NICE) have classified stage 4 breast cancer as moderate in severity.
In developing guidance on whether new medicines can be recommended for routine use in the treatment of NHS patients, NICE is able to apply a weighting that recognises the additional value that society places on treatments for severe conditions. The weighting that is applied is calculated for each appraisal based on information on the expected shortfall in life expectancy and quality of life of people with the condition, taking into account existing treatment options. NICE has concluded for several appraisals of medicines for late-stage breast cancer that a weighting should be applied based on the severity of the condition.